Table 4.
Evaluation of staining performance of monoclonal antibody in the context of multicolor analysis
| Tested Markers | Evaluated Sample, na | Signal-to-Noise | ||
|---|---|---|---|---|
| Mean ± SD | Range | Recommended | ||
| CD45 | 10 | 323.7 ± 101 | 226 – 573.2 | >100 |
| CD19 | 10 | 134.5 ± 56.6 | 37.6 – 215.3 | >10 |
| CD27 | 10 | 20.7 ± 6.9 | 10.3 – 32.1 | >5 |
| CD81 | 10 | 25.3 ± 12.2 | 11.8 – 49.4 | >5 |
| CD56 | 10 | 50.1 ± 25.1 | 32 – 114.9 | >10 |
| CD117 | 10 | 46.1 ± 31 | 15.2 – 99.9 | >10 |
| CD138 | 10 | 83.9 ± 46.3 | 30.9 – 144.3 | >10 |
| CD38 | 10 | 19.5 ± 9.8 | 4.8 – 36.0 | >3 |
| cKappa | 10 | 18 ± 13.2 | 4.9 – 45.2 | >3 |
| cLambda | 10 | 13.5 ± 5.4 | 5.8 – 25.4 | >3 |
a
Ten random patient bone marrow samples received for flow cytometric evaluation which had no evidence of hematological disease by flow cytometry or histopathological assessment